Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan

Masato Tashiro; Koichi Izumikawa; Asuka Minematsu; Katsuji Hirano; Naoki Iwanaga; Shotaro Ide; Tomo Mihara; Naoki Hosogaya; Takahiro Takazono; Yoshitomo Morinaga; Shigeki Nakamura; Shintaro Kurihara; Yoshifumi Imamura; Taiga Miyazaki; Tomoya Nishino; Misuzu Tsukamoto; Hiroshi Kakeya; Yoshihiro Yamamoto; Katsunori Yanagihara; Akira Yasuoka; Takayoshi Tashiro; Shigeru Kohno

doi:10.1128/AAC.05394-11

Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan

Masato Tashiro, Koichi Izumikawa^*, Asuka Minematsu, Katsuji Hirano, Naoki Iwanaga, Shotaro Ide, Tomo Mihara, Naoki Hosogaya, Takahiro Takazono, Yoshitomo Morinaga, Shigeki Nakamura, Shintaro Kurihara, Yoshifumi Imamura, Taiga Miyazaki, Tomoya Nishino, Misuzu Tsukamoto, Hiroshi Kakeya, Yoshihiro Yamamoto, Katsunori Yanagihara, Akira YasuokaTakayoshi Tashiro, Shigeru Kohno

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

76 Scopus citations

Abstract

We investigated the triazole, amphotericin B, and micafungin susceptibilities of 196 A. fumigatus clinical isolates in Nagasaki, Japan. The percentages of non-wild-type (non-WT) isolates for which MICs of itraconazole, posaconazole, and voriconazole were above the ECV were 7.1%, 2.6%, and 4.1%, respectively. A G54 mutation in cyp51A was detected in 64.2% (9/14 isolates) and 100% (5/5 isolates) of non-WT isolates for itraconazole and posaconazole, respectively. Amphotericin B MICs of ≥2 μg/ml and micafungin minimum effective concentrations (MECs) of ≥16 μg/ml were recorded for two and one isolates, respectively.

Original language	English
Pages (from-to)	584-587
Number of pages	4
Journal	Antimicrobial Agents and Chemotherapy
Volume	56
Issue number	1
DOIs	https://doi.org/10.1128/AAC.05394-11
State	Published - 2012/01

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/AAC.05394-11

Cite this

Tashiro, M., Izumikawa, K., Minematsu, A., Hirano, K., Iwanaga, N., Ide, S., Mihara, T., Hosogaya, N., Takazono, T., Morinaga, Y., Nakamura, S., Kurihara, S., Imamura, Y., Miyazaki, T., Nishino, T., Tsukamoto, M., Kakeya, H., Yamamoto, Y., Yanagihara, K., ... Kohno, S. (2012). Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan. Antimicrobial Agents and Chemotherapy, 56(1), 584-587. https://doi.org/10.1128/AAC.05394-11

@article{db492112e7ae4f7d8121829dc9aa6c34,

title = "Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan",

abstract = "We investigated the triazole, amphotericin B, and micafungin susceptibilities of 196 A. fumigatus clinical isolates in Nagasaki, Japan. The percentages of non-wild-type (non-WT) isolates for which MICs of itraconazole, posaconazole, and voriconazole were above the ECV were 7.1%, 2.6%, and 4.1%, respectively. A G54 mutation in cyp51A was detected in 64.2% (9/14 isolates) and 100% (5/5 isolates) of non-WT isolates for itraconazole and posaconazole, respectively. Amphotericin B MICs of ≥2 μg/ml and micafungin minimum effective concentrations (MECs) of ≥16 μg/ml were recorded for two and one isolates, respectively.",

author = "Masato Tashiro and Koichi Izumikawa and Asuka Minematsu and Katsuji Hirano and Naoki Iwanaga and Shotaro Ide and Tomo Mihara and Naoki Hosogaya and Takahiro Takazono and Yoshitomo Morinaga and Shigeki Nakamura and Shintaro Kurihara and Yoshifumi Imamura and Taiga Miyazaki and Tomoya Nishino and Misuzu Tsukamoto and Hiroshi Kakeya and Yoshihiro Yamamoto and Katsunori Yanagihara and Akira Yasuoka and Takayoshi Tashiro and Shigeru Kohno",

year = "2012",

month = jan,

doi = "10.1128/AAC.05394-11",

language = "英語",

volume = "56",

pages = "584--587",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "1",

}

Tashiro, M, Izumikawa, K, Minematsu, A, Hirano, K, Iwanaga, N, Ide, S, Mihara, T, Hosogaya, N, Takazono, T, Morinaga, Y, Nakamura, S, Kurihara, S, Imamura, Y, Miyazaki, T, Nishino, T, Tsukamoto, M, Kakeya, H, Yamamoto, Y, Yanagihara, K, Yasuoka, A, Tashiro, T & Kohno, S 2012, 'Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan', Antimicrobial Agents and Chemotherapy, vol. 56, no. 1, pp. 584-587. https://doi.org/10.1128/AAC.05394-11

TY - JOUR

T1 - Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan

AU - Tashiro, Masato

AU - Izumikawa, Koichi

AU - Minematsu, Asuka

AU - Hirano, Katsuji

AU - Iwanaga, Naoki

AU - Ide, Shotaro

AU - Mihara, Tomo

AU - Hosogaya, Naoki

AU - Takazono, Takahiro

AU - Morinaga, Yoshitomo

AU - Nakamura, Shigeki

AU - Kurihara, Shintaro

AU - Imamura, Yoshifumi

AU - Miyazaki, Taiga

AU - Nishino, Tomoya

AU - Tsukamoto, Misuzu

AU - Kakeya, Hiroshi

AU - Yamamoto, Yoshihiro

AU - Yanagihara, Katsunori

AU - Yasuoka, Akira

AU - Tashiro, Takayoshi

AU - Kohno, Shigeru

PY - 2012/1

Y1 - 2012/1

N2 - We investigated the triazole, amphotericin B, and micafungin susceptibilities of 196 A. fumigatus clinical isolates in Nagasaki, Japan. The percentages of non-wild-type (non-WT) isolates for which MICs of itraconazole, posaconazole, and voriconazole were above the ECV were 7.1%, 2.6%, and 4.1%, respectively. A G54 mutation in cyp51A was detected in 64.2% (9/14 isolates) and 100% (5/5 isolates) of non-WT isolates for itraconazole and posaconazole, respectively. Amphotericin B MICs of ≥2 μg/ml and micafungin minimum effective concentrations (MECs) of ≥16 μg/ml were recorded for two and one isolates, respectively.

AB - We investigated the triazole, amphotericin B, and micafungin susceptibilities of 196 A. fumigatus clinical isolates in Nagasaki, Japan. The percentages of non-wild-type (non-WT) isolates for which MICs of itraconazole, posaconazole, and voriconazole were above the ECV were 7.1%, 2.6%, and 4.1%, respectively. A G54 mutation in cyp51A was detected in 64.2% (9/14 isolates) and 100% (5/5 isolates) of non-WT isolates for itraconazole and posaconazole, respectively. Amphotericin B MICs of ≥2 μg/ml and micafungin minimum effective concentrations (MECs) of ≥16 μg/ml were recorded for two and one isolates, respectively.

UR - http://www.scopus.com/inward/record.url?scp=84455170016&partnerID=8YFLogxK

U2 - 10.1128/AAC.05394-11

DO - 10.1128/AAC.05394-11

M3 - 学術論文

C2 - 22024829

AN - SCOPUS:84455170016

SN - 0066-4804

VL - 56

SP - 584

EP - 587

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 1

ER -

Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan

Abstract

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this